Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Involvement of the glutamine RF‑amide peptide and its cognate receptor GPR103 in prostate cancer

Tools
- Tools
+ Tools

Kawan, Mohamed, Kyrou, Ioannis, Ramanjaneya, Manjunath, Williams, Kevin, Jeyaneethi, Jeyarooban, Randeva, Harpal S. and Karteris, Emmanouil (2019) Involvement of the glutamine RF‑amide peptide and its cognate receptor GPR103 in prostate cancer. Oncology Reports, 41 (2). pp. 1140-1150. doi:10.3892/or.2018.6893

Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.3892/or.2018.6893

Request Changes to record.

Abstract

Glutamine RF‑amide peptide (QRFP) belongs to the RFamide neuropeptide family, which is involved in a wide spectrum of biological activities, ranging from food intake and cardiovascular functioning to analgesia, aldosterone secretion, locomotor activity and reproduction. Recently, QRFP has been demonstrated to exert its effects by activating the G protein‑coupled receptor GPR103. QRFP is expressed in the brain and peripherally in the adipose tissue, bladder, colon, testis, parathyroid and thyroid gland, as well as in the prostate gland. Following lung cancer, prostate cancer constitutes the second most frequently diagnosed cancer among men, whilst obesity appears to be a contributing factor for aggressive prostate cancer. In the present study, we sought to investigate the role of QRFP in prostate cancer, using two androgen‑independent human prostate cancer cell lines (PC3 and DU145) as in vitro experimental models and clinical human prostate cancer samples. The expression of both QRFP and GPR103 at the gene and protein level was higher in human prostate cancer tissue samples compared to control and benign prostatic hyperplasia (BHP) samples. Furthermore, in both prostate cancer cell lines used in the present study, QRFP treatment induced the phosphorylation of ERK1/2, p38, JNK and Akt. In addition, QRFP increased cell migration and invasion in these in vitro models, with the increased expression of MMP2. Furthermore, we demonstrated that the pleiotropic adipokine, leptin, increased the expression of QRFP and GPR103 in PC3 prostate cancer cells via a PI3K‑ and MAPK‑dependent mechanism, indicating a novel potential link between adiposity and prostate cancer. Our findings expand the existing evidence and provide novel insight into the implication of QRFP in prostate cancer.

Item Type: Journal Article
Divisions: Faculty of Medicine > Warwick Medical School
Journal or Publication Title: Oncology Reports
Publisher: Spandidos Publications
ISSN: 1021-335X
Official Date: February 2019
Dates:
DateEvent
February 2019Published
10 June 2018Accepted
Volume: 41
Number: 2
Page Range: pp. 1140-1150
DOI: 10.3892/or.2018.6893
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access
Copyright Holders: © Kawan et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us